CXCL8 and hepatocellular carcinoma: Therefore, we believe that the immunological interaction of TARE and IL-8 needs to be investigated in future studies, as well as the association of IL-8 with immunotherapies, which have become the standard first-line treatment for HCC (EASL 2018, Vogel et al. 2021).